Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder. Show more
Location: | Website: myovant.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$26.99
Open
$26.99
Volume
2,256,078
Day Range
$26.98 - $27.00
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
48.61%
Institutional Own.
56.21%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ORGOVYX (Relugolix) (GnRH receptor antagonist) Details Prostate Cancer | Approved Quarterly sales | |
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Reproductive disease, Endometriosis, Uterine disease | Approved Quarterly sales | |
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Uterine Fibroids | Approved Quarterly sales |